Related references
Note: Only part of the references are listed.The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A US SEER database analysis
Hee Jeong Kim et al.
BREAST (2022)
Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer
Adrienne G. Waks et al.
CLINICAL CANCER RESEARCH (2022)
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
P. A. Fasching et al.
ANNALS OF ONCOLOGY (2021)
Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype
Ralitsa Madsen et al.
PLOS GENETICS (2021)
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
Olivia Pagani et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical utility of genomic signatures in young breast cancer patients: a systematic review
Cynthia Villarreal-Garza et al.
NPJ BREAST CANCER (2020)
Clinical implications of prospective genomic profiling of metastatic breast cancer patients
Courtney T. van Geelen et al.
BREAST CANCER RESEARCH (2020)
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups
Oscar M. Rueda et al.
NATURE (2019)
Genomic characterization of metastatic breast cancers
Francois Bertucci et al.
NATURE (2019)
Detecting the mutational signature of homologous recombination deficiency in clinical samples
Doga C. Gulhan et al.
NATURE GENETICS (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Neil Vasan et al.
SCIENCE (2019)
Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data
Dimitrios Zardavas et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
Ellen R. Copson et al.
LANCET ONCOLOGY (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
P. A. Francis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial
Stephen J. Luen et al.
JAMA ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
Poornima Saha et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Helen Davies et al.
NATURE MEDICINE (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival
Ann H. Partridge et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Serena Nik-Zainal et al.
NATURE (2016)
Genomic aberrations in young and elderly breast cancer patients
Hatem A. Azim et al.
BMC MEDICINE (2015)
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
Meredith M. Regan et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Prudence A. Francis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Estrogen signaling and the DNA damage response in hormone dependent breast cancers
C. Elizabeth Caldoe
FRONTIERS IN ONCOLOGY (2014)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2013)
A new genome-driven integrated classification of breast cancer and its implications
Sarah-Jane Dawson et al.
EMBO JOURNAL (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling
Hatem A. Azim et al.
CLINICAL CANCER RESEARCH (2012)
Whole-genome analysis informs breast cancer response to aromatase inhibition
Matthew J. Ellis et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis et al.
NATURE (2012)
Share Paper
